Department of Gynecologic Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, China.
Department of Obstetrics and Gynecology, Shandong Maternity and Child Health Care Hospital, Jinan 250014, China.
Jpn J Clin Oncol. 2019 Aug 1;49(8):714-718. doi: 10.1093/jjco/hyz057.
The current study was aimed to evaluate the efficacy and toxicity of postoperative adjuvant chemotherapy (CT) combined with intracavitary brachytherapy (ICRT) in cervical cancer patients with intermediate-risk.
We analyzed the medical records of 558 patients who were submitted to radical surgery for Stage IB-IIA cervical cancer. A total of 172 of those 558 patients were considered intermediate-risk according to the GOG criteria. Among those 172 patients, 102 were subjected to CT combined with ICRT (CT+ICRT) and the remaining 70 patients were treated with concurrent chemoradiation (CCRT). The 3-year disease free survival (DFS), overall survival (OS), and complications of each group were evaluated and analyzed.
No significant difference was observed in 3-year DFS or OS of the patients submitted to CT+ICRT and CCRT. Importantly, the frequencies of grade III to IV acute complications were significantly higher in patients submitted to CCRT than in those treated with CT+ICRT (Hematologic, P = 0.016; Gastrointestinal, P = 0.041; Genitourinary, P = 0.019). Moreover, the frequencies of grade III-IV late complications in patients treated with CCRT were significantly higher compared with CT+ICRT-treated patients (Gastrointestinal, P = 0.026; Genitourinary, P = 0.026; Lower extremity edema, P = 0.008).
Postoperative adjuvant CT+ICRT treatment achieved equivalent 3-year DFS and OS but low complication rate compared to CCRT treatment in early stage cervical cancer patients with intermediate-risk.
本研究旨在评估中危宫颈癌患者术后辅助化疗(CT)联合腔内近距离放疗(ICRT)的疗效和毒性。
我们分析了 558 例接受根治性手术治疗的 IB-IIA 期宫颈癌患者的病历。根据 GOG 标准,其中 172 例患者被认为是中危患者。在这 172 例患者中,102 例接受 CT 联合 ICRT(CT+ICRT)治疗,其余 70 例接受同期放化疗(CCRT)。评估并分析了每组患者的 3 年无病生存率(DFS)、总生存率(OS)和并发症。
接受 CT+ICRT 和 CCRT 治疗的患者 3 年 DFS 或 OS 无显著差异。重要的是,CCRT 组患者的 3-4 级急性并发症发生率明显高于 CT+ICRT 组(血液学,P=0.016;胃肠道,P=0.041;泌尿生殖系统,P=0.019)。此外,CCRT 组患者 3-4 级晚期并发症的发生率明显高于 CT+ICRT 组(胃肠道,P=0.026;泌尿生殖系统,P=0.026;下肢水肿,P=0.008)。
与 CCRT 相比,中危宫颈癌患者术后辅助 CT+ICRT 治疗可获得等效的 3 年 DFS 和 OS,但并发症发生率较低。